biote Corp. (BTMD) vs INmune Bio, Inc. (INMB)
A side-by-side comparison of biote Corp. and INmune Bio, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
BTMD
biote Corp.
$1.17HealthcareDelayed quote: Oct 6, 2026, 12:55 PM EDT
INMB
INmune Bio, Inc.
$1.89HealthcareDelayed quote: Oct 6, 2026, 12:48 PM EDT
Total return — BTMD vs INMB
growth of $100 · dividends reinvested · last 5yBTMD -88.9% (-35.5%/yr)INMB -83.7% (-30.4%/yr)INMB compounded faster over this window
BTMD INMB
BTMD vs INMB: by the numbers
- •BTMD is the larger company ($52M vs $50M market cap).
- •BTMD is profitable (3.19% net margin) while INMB runs a net loss (-91866.00%).
Metrics side by side
Valuation
| Metric | BTMD | INMB |
|---|---|---|
| P/E ratio | 10.03 | N/A |
| P/S ratio | 0.28 | N/A |
| P/B ratio | N/A | 2.47 |
| EV / EBITDA | 9.09 | N/A |
| FCF yield | 38.14% | N/A |
Profitability
| Metric | BTMD | INMB |
|---|---|---|
| Gross margin | 71.46% | 100.00% |
| Operating margin | 18.50% | -61738.00% |
| Net margin | 3.19% | -91866.00% |
| ROE | N/A | -90.44% |
| ROIC | 13.63% | -96.37% |
Growth (annualized)
| Metric | BTMD | INMB |
|---|---|---|
| Revenue CAGR (5Y) | 10.52% | N/A |
| EPS CAGR (5Y) | -25.90% | N/A |
| FCF CAGR (5Y) | 3.81% | N/A |
| Total return CAGR (5Y) | -35.12% | -36.88% |
Frequently asked
- Is BTMD or INMB more profitable?
- BTMD runs the higher net margin — BTMD at 3.19% versus INMB at -91866.00%.
- How have BTMD and INMB total returns compared?
- Over the past 5 years, BTMD delivered -35.12% and INMB delivered -36.88% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
biote P/E ratiobiote ROEINmune Bio ROEbiote operating marginINmune Bio operating marginbiote revenue growthINmune Bio revenue growthbiote free cash flowINmune Bio free cash flow
biote & INmune Bio appear in these rankings
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.